Combination of Erlotinib and Bevacizumab as Second-line Treatment in Patients With Non-small Cell Lung Cancer
Status:
Terminated
Trial end date:
2010-09-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the efficacy and toxicity of combination of
erlotinib and bevacizumab in patients with locally advanced or metastatic, non-squamous
non-small cell lung cancer, who progressed after first line treatment. Pretreatment with one
of the two agents would not excluded patients from the study, in order to evaluate whether
the combination of the two biologic agents could reverse tumor resistance.